Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: Potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 1, 2011, Pages 37-45

  Zhu, Zhen Wei ^a   Shi, Lei ^a   Ruan, Xiao Ming ^a   Yang, Ying ^a   Li, Huan Qiu ^a   Xu, Suo Ping ^a   Zhu, Hai Liang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

antiproliferative activities; docking simulations; EGFR TK; Salicylanilide derivatives; structure activity relationship

Indexed keywords

2 HYDROXY 4 METHYL N 4 TOLYLBENZAMIDE; 2 HYDROXY 4 METHYL N PHENYLBENZAMIDE; 2 HYDROXY N (4 ISOPROPYLPHENYL) 4 METHYLBENZAMIDE; 2 HYDROXY N (4 ISOPROPYLPHENYL)BENZAMIDE; 2 HYDROXY N (4 METHOXYPHENYL)BENZAMIDE; 2 HYDROXY N 4 TOLYLBENZAMIDE; 2 HYDROXY N PHENYLBENZAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FLUOROURACIL; N (2 BROMOPHENYL) 2 HYDROXY 4 METHYLBENZAMIDE; N (2 BROMOPHENYL) 2 HYDROXY 5 IODOBENZAMIDE; N (2 BROMOPHENYL) 2 HYDROXYBENZAMIDE; N (2 CHLOROPHENYL) 2 HYDROXY 5 IODOBENZAMIDE; N (2 CHLOROPHENYL) 2 HYDROXYBENZAMIDE; N (2 FLUOROPHENYL) 2 HYDROXYBENZAMIDE; N (2,4 DICHLOROPHENYL) 2 HYDROXY 4 METHYLBENZAMIDE; N (2,4 DICHLOROPHENYL) 2 HYDROXY 5 IODOBENZAMIDE; N (2,4 DICHLOROPHENYL) 2 HYDROXYBENZAMIDE; N (2,4 DIFLUOROPHENYL) 2 HYDROXY 4 METHYLBENZAMIDE; N (2,4 DIFLUOROPHENYL) 2 HYDROXYBENZAMIDE; N (4 BROMOPHENYL) 2 HYDROXY 5 IODOBENZAMIDE; N (4 BROMOPHENYL) 2 HYDROXYBENZAMIDE; N (4 CHLOROPHENYL) 2 HYDROXY 4 METHYLBENZAMIDE; N (4 CHLOROPHENYL) 2 HYDROXY 5 IODOBENZAMIDE; N (4 CHLOROPHENYL) 2 HYDROXYBENZAMIDE; N (4 FLUOROPHENYL) 2 HYDROXY 4 METHYLBENZAMIDE; N (4 FLUOROPHENYL) 2 HYDROXY 5 IODOBENZAMIDE; N (4 FLUOROPHENYL) 2 HYDROXYBENZAMIDE; SALICYLANILIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ELEMENTAL ANALYSIS; ENZYME ACTIVE SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; FLUOROURACIL; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR DYNAMICS SIMULATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALICYLANILIDES; SALICYLIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLIUM SALTS; THIAZOLES;

EID: 79851475397     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756361003671060     Document Type: Article

References (26)

1. Burkhart DJ, Barthel BL, Post GC, Kalet BT, Nafe JW, Shoemaker RK, Koch TH. Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases. J Med Chem 2006;49:7002-7012. (Pubitemid 44885988)
2. Ksander GM, de Jesus R, Yuan A, Fink C, Moskal M, Carlson E, Kukkola P, Bilci N, Wallace E, Neubert A, Feldman D, Mogelesky T, Poirier K, Jeune M, Steele R, Wasvery J, Stephan Z, Cahill E, Webb R, Navarrete A, Lee W, Gibson J, Alexander N, Sharif H, Hospattankar A. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J Med Chem 2001;44:4677-4687. (Pubitemid 33144477)
3. Ou TM, Lu YJ, Zhang C, Huang ZS, Wang XD, Tan JH, Chen Y, Ma DL, Wong KY, Tang JCO, Chan ASC, Gu LQ. Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem 2007;50:1465-1474. (Pubitemid 46566333)
4. Hsieh PW, Chang FR, Wu CC, Wu KY, Li CM, Chen SL, Wu YC. New cytotoxic cyclic peptides and dianthramide from Dianthus superbus. J Nat Prod 2004;67:1522-1527.
5. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. A specifc inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-1995.
6. Ward WHJ, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994;48:659-666.
7. Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A. 6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001;44:2719-2734. (Pubitemid 32879714)
8. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HDH, Fry DW, Kraker AJ, Denny W. Tyrosine kinase inhibitors 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7- dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth receptor. J Med Chem 1996;39:267-276.
9. Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, Jean-Claude BJ. Te combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor rceptor (EGFR). J Med Chem 2006;49:3544-3552. (Pubitemid 43902460)
10. Kamath S, Buolamwini JK. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J Med Chem 2003;46:4657-4668. (Pubitemid 37271615)
11. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor.mediated signaling by "combi-triazene" BJ2000, a new probe for combi-targeting postulates. J Pharmacol Exp Ter 2002;303:238-246.
12. Matheson SL, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ter 2001;296:832-840. (Pubitemid 32187355)
13. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TPJ. Expression of epidermal growth-factor receptor and proliferating cell nuclear antigen predicts response of neophageal squamous-cell carcinoma to chemoradiotherapy. Cancer 1994;74:1693-1698. (Pubitemid 24301821)
14. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Mol Cell Biol 2001;2:127-137. (Pubitemid 33674041)
15. Hynes NE, Stern DF. Te biology of ErbB-2 neu her-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-184.
16. Gullick WJ. Prevalence of aberrant expression of the epidermal growth-factor receptor in human cancers. Br Med Bull 1991;47:87-98.
17. Moscatello DK, Holgado-Mudruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. Frequent expression of a mutant epidermal growth-factor receptor in multiple human tumors. Cancer Res 1995;55:5536-5539.
18. Wikstrand C J, McLendon RE, Friedman A, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57:4130-4140. (Pubitemid 27427708)
19. Bridges AJ. Te rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999;6:825-843. (Pubitemid 29422197)
20. Boschelli DH. Small molecule inhibitors of receptor tyrosine kinases. Drugs Future 1999;24:515-537. (Pubitemid 29304797)
21. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-1662. (Pubitemid 128590223)
22. Goodsell DS, Morris GM, Olson AJ, Automated docking of fexible ligands: applications of AutoDock. J. Mol. Recognit. 1996;9,1-5. (Pubitemid 126565462)
23. Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force feld with charge-based desolvation. J Comput Chem 2007;28:1145-1152. (Pubitemid 46506716)
24. Pless SA, Millen KS, Hanek AP, Lynch JW, Lester HA, Lummis SCR, Dougherty DA. A cation-pi interaction in the binding site of the glycine receptor is mediated by a phenylalanine residue. J Neurosci 2008;28:10937-10942.
25. Xiao ZP, Li HQ, Shi L, Lv PC, Song ZC, Zhua HL. Synthesis, antiproliferative activity, and structure-activity relationships of 3-aryl-1H-quinolin-4-ones. Chem Med Chem 2008;3:1077-1082.
26. Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001;44:2719-2734. (Pubitemid 32879714)